Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
MYRIAD GENETICS INC (MYGN)
A forensic read on MYRIAD GENETICS INC built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-5.9
Altman Z-score
Clean
Earnings quality
5
Forensic signals
-109.1%
ROE
$555M
Market cap
MYRIAD GENETICS INC earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is -5.9, placing it in the Distress zone. 5 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-63%Return on invested capital.Return on invested capital is -63% and slipping from -11% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+5.0%/yrShare-count dilution.Diluted share count changed +15% over the last 3 years to FY2025 (+5.0%/yr). The count is GROWING — existing holders are being diluted. That's ~5.0% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~15%.
stoppedShareholder returns — halted.Capital returns have STOPPED — $50M of buybacks + dividends in FY2019, but ~$0 in FY2021. A halt usually means the company is conserving cash; understand why before reading it as neutral.
45dInventory days.Days inventory outstanding moved from 40 to 45 FY2024→FY2025 (against cost of goods sold; inventory +11% vs -2% in cost of sales). Inventory is building a little faster than sales — watch for markdowns.
$318MGoodwill impairments.Took $318M of goodwill writedowns across 3 year(s) (FY2020 ($82M), FY2024 ($800,000), FY2025 ($235M)). Writedowns mean past acquisitions underperformed what was paid for them — worth weighing on capital-allocation skill.
Key fundamentals
Net Margin-44.4%
Debt / Equity0.49x
Free Cash Flow$-13.8M
Latest Revenue$824.5M
Return on Equity-99.4%
Revenue Growth YoY-1.6%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on MYRIAD GENETICS INC:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about MYGN's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown